Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrew Gewitz"'
Autor:
Andrew Gewitz, Jeanne Mendell, Yuhuan Wang, Charles Harris, Benjamin A. Olenchock, Simona Podgrabinska, Wenjun Zheng, An Zhao, Hao Pan, Frédéric Vanhoutte, John D. Davis
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract Mibavademab (previously known as REGN4461), a fully human monoclonal antibody, is being investigated for the treatment of conditions associated with leptin deficiency. Here, we report pharmacokinetics (PKs), pharmacodynamics, and immunogenic
Externí odkaz:
https://doaj.org/article/3a53c650addb4dff9fd51a0f804d2d33
Autor:
Robert S. Rosenson, Daniel Gaudet, Christie M. Ballantyne, Seth J. Baum, Jean Bergeron, Erin E. Kershaw, Patrick M. Moriarty, Paolo Rubba, David C. Whitcomb, Poulabi Banerjee, Andrew Gewitz, Claudia Gonzaga-Jauregui, Jennifer McGinniss, Manish P. Ponda, Robert Pordy, Jian Zhao, Daniel J. Rader
Publikováno v:
Nature Medicine. 29:729-737
Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and prevent acute pancreatitis. This phase 2 trial (NCT03452228) evaluated
Autor:
Pamela N. Munster, Scott Thomas, Tayeba Maktabi, Robin K. Kelley, Mark Moasser, Amy J. Chien, Andrew Gewitz, Jennifer A. Grabowsky, Manuela Terranova-Barberio, Nela Pawlowska, Jenna Z. Zhang, Jim Leng, Rahul Raj Aggarwal, Imke H. Bartelink, Mallika S. Dhawan
Purpose: The PARP inhibitor (PARPi) talazoparib may potentiate activity of chemotherapy and toxicity in cells vulnerable to DNA damage.Experimental Design: This phase I study evaluated the safety, tolerability, pharmacokinetics, and efficacy of talaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fef46cd79198719c484e725942900fd
https://doi.org/10.1158/1078-0432.c.6527073
https://doi.org/10.1158/1078-0432.c.6527073
Autor:
Pamela N. Munster, Scott Thomas, Tayeba Maktabi, Robin K. Kelley, Mark Moasser, Amy J. Chien, Andrew Gewitz, Jennifer A. Grabowsky, Manuela Terranova-Barberio, Nela Pawlowska, Jenna Z. Zhang, Jim Leng, Rahul Raj Aggarwal, Imke H. Bartelink, Mallika S. Dhawan
Supplementary table 1 Observed and predicted blood toxicity profile at the start of Cycle 2 and Cycle 4 (A) and PK-toxicity model-predicted (B) neutrophil and platelet toxicity at cycle 2, day 1 and cycle 5 talozaparib 1mg/carboplatin AUC 1/5 weekly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439740471efabc624e71188857a3a7e0
https://doi.org/10.1158/1078-0432.22468851.v1
https://doi.org/10.1158/1078-0432.22468851.v1